Company Overview and News

0
Orient Cement shares jump nearly 7% on deal call-off

2018-05-31 moneycontrol
Shares of Orient Cement surged nearly 7 percent after the company announced the termination of the agreement to acquire two entities from Jaypee group firms. The stock surged 6.57 percent to end at Rs 129 on BSE. Intra-day, it jumped 15.24 percent to Rs 139.50.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

0
Jaiprakash Power Ventures Limited - Updates

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

0
Orient Cement stock jumps 15% after deal to buy 2 units from Jaypee called off

2018-05-31 moneycontrol
Orient Cement share price rallied more than 15 percent intraday Thursday after the company called off a deal to acquire 2 units from Jaypee. Jaiprakash Associates lost 3 percent.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

41
Market Live: Sensex up 150 pts, Midcap underperforms; Tech Mahindra, ONGC jump

2018-05-31 moneycontrol
Indian Oil Corporation, which has for decades been India's biggest company by turnover, last week posted a record net profit of Rs 21,346 crore in the fiscal year ended March 31, 2018 (FY 2017-18), up 12 per cent from Rs 19,106 crore in the last fiscal.
IOC 500325 JIPKY BHUSANSTL TCHQY 532755 532754 535754 UCLQY 500570 CLNDY 500055 RLNIY 500413 AXB EVSJF 532627 530965 ULTRACEMCO TECHM 500182 AXBA 500180 520051 TCS COALINDIA RELIANCE PUNJLLOYD GMQRY GMRINFRA 532538 TTNQY 533278 532215 THOMASCOOK 532540 AXISBANK RIGD HDFCBANK HEROMOTOCO TATAMOTORS ORIENTCEM ESI IBN UCLQF JPASSOCIAT 539207 AXBKY 532532 ICICIBANK 532693 HDB 532174 JAMNAAUTO JPPOWER HRTQY MANPASAND TTM

0
Orient Cement calls off deal to acquire 2 units from Jaypee

2018-05-31 moneycontrol
CK Birla Group firm Orient Cement has terminated the agreement to acquire two entities, Bhilai Jaypee Cement and Nigrie Cement Grinding Unit, from Jaypee group firms for a total consideration of Rs 1,946 crore.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

0
Jaiprakash Power Ventures Q4 loss at Rs157.62 crore

2018-05-05 livemint
New Delhi: Jaiprakash Power Ventures on Saturday reported a net loss of Rs157.62 crore for the fourth quarter ended 31 March 2018. The company had posted a net loss of Rs 229.39 crore in the same period of the previous fiscal.
532627 JPPOWER

0
Jaiprakash Power Ventures Limited - Financial Result Updates

2018-05-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

0
JSW Energy mulls taking Jaiprakash Power to NCLT

2018-05-04 freepressjournal.in
Mumbai : Sajjan Jindal-led JSW Energy is considering initiating Insolvency and Bankruptcy Code (IBC) resolution process against Jaiprakash Power Ventures (JPVL). At present, the company and lenders are discussing with JPVL to find a solution and speed up the recovery process.
532627 JPPOWER JSWENERGY 533148

0
JSW Energy reports Rs480 crore loss in March quarter

2018-05-03 livemint
Mumbai: JSW Energy on Thursday reported consolidated net loss of Rs480.05 crore in the January-March quarter of this fiscal, compared to a net profit of Rs24.76 crore in the year-ago period.
532627 JPPOWER JSWENERGY 533148

8
ICICI case: BBB member’s Avista stint under scanner

2018-04-17 freepressjournal.in
New Delhi : The finance ministry is looking at the professional assistance provided by newly-appointed Banks Board Bureau (BBB) member P Pradeep Kumar during his stint at Avista Advisory Group, which is caught in the controversy involving ICICI Bank and Videocon Group, sources said.
JIPKY IBN 532627 532505 JPASSOCIAT 530323 532775 GTLINFRA 532532 ICICIBANK 532174 ERAINFRA JPPOWER UCOBANK SBAZ

0
Jaiprakash Power Ventures Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

8
Doubts linger on Rajiv Kochhar role in ICICI Bank loan mess

2018-04-03 freepressjournal.in
Mumbai : Media is thick with reports about investigations being undertaken about financial affairs at ICICI Bank. It is now the turn of the Central Bureau of Investigation (CBI) to begin questioning of not just ICICI Bank officials but also the Kochhars — Chanda and her husband, Deepak. But there is one more Kochhar whose activities in the financial markets may be worth investigating. The person is Rajiv Kochhar, Deepak Kochhar’s brother.
JIPKY IBN 512299 532418 532627 JPASSOCIAT 532532 ICICIBANK SLTHY STERLINBIO 532174 JPPOWER ANDHRABANK SBAZ

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...